Renalytix Plc (LON:RENX – Get Free Report) was up 30.1% during trading on Tuesday . The stock traded as high as GBX 6 and last traded at GBX 5.40. Approximately 4,418,656 shares changed hands during trading, an increase of 374% from the average daily volume of 931,928 shares. The stock had previously closed at GBX 4.15.
Renalytix Price Performance
The firm’s 50 day moving average price is GBX 3.34 and its two-hundred day moving average price is GBX 2.63. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42. The stock has a market cap of £23.60 million, a PE ratio of -1.35 and a beta of 1.81.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Stories
- Five stocks we like better than Renalytix
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
- Copper Is the AI Trade No One Priced In—3 Miners With the Most to Gain
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
